Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyRalf Reilmann, Hope Heller, Douglas R. Langbehn et al.|The Lancet Neurology|2018Cited by 108